Trial Information
Effectiveness and Safety as Well as Adherence of the "S3 Guidelines for the Treatment of Prostate Cancer" in the Treatment of Patients of Patients With Firmagon®
Inclusion Criteria:
- advanced hormone-dependent prostate cancer with no other previous hormone therapy for
whom - irrespectively of this NIS -the use of Firmagon® is intended
Exclusion Criteria:
- contraindication for Degarelix
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Outcome Measure:
PSA-/Testosterone Level
Outcome Time Frame:
12 months
Safety Issue:
No
Principal Investigator
Leopold Durner, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
UCM GmbH
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
UCM12-01
NCT ID:
NCT01710098
Start Date:
June 2012
Completion Date:
June 2014
Related Keywords:
- Prostate Cancer
- testosterone
- S3-Adherence
- Quality of Life
- Prostatic Neoplasms